dna-methylation-changes-linked-to-sleep-disorders-may-accelerate-biological-aging
DNA Methylation Changes Linked to Sleep Disorders May Accelerate Biological Aging

DNA Methylation Changes Linked to Sleep Disorders May Accelerate Biological Aging

A comprehensive scientific review published in Frontiers in Neurology has evaluated the expanding biomedical literature connecting epigenetic modifications, specifically DNA methylation, to clinical sleep disturbances and experimental sleep deprivation. Sleep disorders represent a critical global public health concern, with clinically diagnosed conditions affecting between five and fifteen percent of the adult population and broader sleep disturbances compromising ten to thirty percent of adults. In healthy physiology, sleep serves indispensable cellular restorative functions, promoting glymphatic clearance of neurotoxic proteins and metabolic waste from the brain while facilitating oxidative stress buffering and cellular DNA repair across peripheral tissues. Persistent disruption of sleep impairs cognitive function and increases the risk of psychiatric disorders, metabolic diseases, cardiovascular complications, and neurodegenerative conditions. The authors synthesize molecular findings across clinical and experimental contexts, demonstrating that DNA methylation alterations recur across biological pathways, offering a framework to understand individual susceptibility, disease heterogeneity, and downstream health outcomes.

At the molecular scale, DNA methylation is a reversible epigenetic modification wherein a methyl group is enzymatically transferred onto the fifth carbon of cytosine residues within cytosine-guanine dinucleotides to form 5-methylcytosine. This process is mediated by DNA methyltransferases, comprising the maintenance enzyme DNMT1 alongside de novo enzymes DNMT3A and DNMT3B, while active demethylation is directed by ten-eleven translocation enzymes TET1, TET2, and TET3 through oxidation to 5-hydroxymethylcytosine. Initial investigations exploring sleep regulation demonstrated distinct genome-wide methylation profiles in monozygotic twin pairs discordant for diurnal preference. Further candidate gene analyses linked promoter I methylation and genetic variants of the brain-derived neurotrophic factor gene to wake time after sleep onset in older adults. Combined with evidence showing epigenetic regulation of core circadian clock genes, these observations reveal that DNA methylation dynamically interacts with the circadian timing system and homeostatic sleep-wake regulation.

In chronic insomnia, which exhibits an estimated global prevalence of 16.2 percent with severe presentations affecting 7.9 percent of the population, researchers have uncovered substantial candidate gene and epigenome-wide signatures. Two disease-associated intronic elements, designated i6 and 617, in the MEIS1 risk locus for insomnia and restless legs syndrome are hypomethylated in neural cells exhibiting elevated transcript expression, indicating enhancer demethylation during neurodevelopment. In patients diagnosed with bipolar disorder, methylation at specific CpG sites within the GRIN2B promoter, which encodes an NMDA receptor subunit, correlated positively with insomnia severity. Epigenome-wide association profiling in Han Chinese cohorts identified 369 differentially methylated positions and 23 differentially methylated regions distinguishing chronic insomnia patients from controls, identifying LHX6 as the most significant differentially methylated gene. Furthermore, integrative colocalization analyses demonstrated that genetic risk variants for insomnia converge with cortical gene expression and local DNA methylation marks at the MDGA1 neurodevelopmental locus.

Studies evaluating phenotypes closely aligned with insomnia, including delayed sleep onset and insufficient sleep, similarly identify epigenetic shifts across neural, metabolic, and circadian pathways. Among 263 adolescents in the Penn State Child Cohort, subjective and objective delays in sleep initiation were associated with differential leukocyte methylation across circadian regulators such as RASD1 and RAI1, cardiometabolic genes including FADS1, WNK1, and SLC5A6, and neuropsychiatric loci like PRR7, SDK1, and FAM172A. In working men under 50 years of age, insufficient sleep altered methylation patterns across nervous system development genes, specifically ERC2, MAGI2, CAST, and CDK5R1. Furthermore, in 142 Mexican adolescents, delayed sleep midpoint correlated with altered methylation at CpG sites within core circadian genes RORB, PER1, CRY2, and NR1D1, though the cross-sectional nature of these cohorts leaves causal directions unresolved.

A remarkably consistent observation across sleep cohorts is the association between insomnia and accelerated biological aging measured by epigenetic clocks. While first-generation algorithms such as the Horvath, Hannum, and SkinBloodClock models were developed to predict chronological age, second-generation clocks like PhenoAge and GrimAge assess mortality risk and physiological vulnerability, and third-generation measures like DunedinPACE gauge the instantaneous pace of biological aging. In an investigation of 3,795 community-dwelling older adults, insomnia combined with short sleep duration was significantly associated with GrimAge acceleration and faster DunedinPACE values. In older Mexican adults, insomnia correlated with accelerated GrimAge and SkinBloodClock metrics, shorter methylation-estimated telomere length, and global hypomethylation enriched in proteostasis and oxidative stress pathways. Moreover, data from 2,078 postmenopausal women in the Women’s Health Initiative revealed that insomnia symptoms were linked to greater extrinsic epigenetic age acceleration and an increased proportion of late-differentiated CD8+CD28-CD45RA- T cells, with Mendelian randomization indicating a directional causal influence of insomnia on GrimAge acceleration.

In obstructive sleep apnoea, characterized by repetitive upper airway collapse, intermittent hypoxia, and intrathoracic pressure swings, DNA methylation changes cluster heavily within the inflammatory and immune axes. With moderate-to-severe disease affecting 22.6 percent of adults globally and roughly 16 percent of young adults, epigenetic markers track clinical severity and symptom expression. Adults with obstructive sleep apnoea exhibit abnormal toll-like receptor 2 promoter methylation and toll-like receptor 6 gene body hypermethylation, which associate with disease severity and excessive daytime sleepiness. Notably, continuous positive airway pressure therapy partly reverses these toll-like receptor alterations alongside corresponding protein expressions, supporting their promise as therapeutic response biomarkers. Epigenetic changes also involve formyl peptide receptor genes, hypomethylation at the -114 CpG site of the interleukin 1 receptor type 2 promoter associated with nocturnal hypoxaemia, and hypermethylation at the -194 CpG site of speckled protein 140 linked to daytime sleepiness, while FOXP3 intron 1 hypermethylation correlates with systemic inflammation in paediatric cohorts.

Vascular pathways and biological aging mechanisms are likewise altered in obstructive sleep apnoea. In children with the condition, hypermethylation at the -171 CpG site within the eNOS promoter reduces endothelial nitric oxide synthase expression, contributing to endothelial dysfunction. Genome-wide profiling identified altered methylation in the NPR2 and cGMP signaling pathway, where hypomethylation at the -608 and -618 CpG sites in the NPR2 promoter was associated with excessive daytime sleepiness. In experimental animal models, gestational intermittent hypoxia induced long-term metabolic dysfunction and widespread DNA methylation changes in adult male offspring, specifically driving hypermethylation of the adiponectin promoter. Additionally, methylation risk scores integrating CpG sites associated with C-reactive protein correlated with apnoea severity and attenuated the statistical associations between sleep-disordered breathing and comorbid hypertension or diabetes, while murine models revealed hippocampal TET1-mediated hydroxymethylation changes driving cognitive deficits under intermittent hypoxia.

In narcolepsy, a central disorder of hypersomnolence affecting 19.1 per 100,000 individuals for type 1 and 23.3 per 100,000 for type 2, epigenetic evidence strongly reinforces an autoimmune pathogenic model. Narcolepsy type 1 is characterized by the selective loss or inactivation of orexin-producing neurons in the lateral hypothalamus, with peak onset around 15 years of age. Japanese patients with type 1 narcolepsy show marked hypomethylation across HLA class II loci in CD4+ and CD8+ T cells driven by the HLA-DQB1*06:02 risk allele. Epigenome-wide studies also identified differential methylation at the CCR3 chemokine receptor locus alongside hypomethylation of CCL5, CCR4, and S100A4 in T cells, which regulate immune cell migration and proliferation. Post-mortem hypothalamic profiling revealed methylation signatures overlapping with multiple sclerosis, centered near the myelin basic protein locus. Intriguingly, patients display promoter hypermethylation of HCRT, CRH, and PDYN alongside preserved or elevated QRFP expression, suggesting that some orexin neurons remain physically intact but suffer functional neuropeptide silencing. Epigenetic involvement is further demonstrated in ADCA-DN, where pathogenic DNMT1 mutations induce widespread promoter hypermethylation.

In restless legs syndrome and shift work sleep disorder, DNA methylation patterns provide insights into neurodevelopmental excitability, occupational misalignment, and clinical recovery. Restless legs syndrome, affecting roughly three percent of the general population and 25.4 percent of psychiatric cohorts, exhibits MDGA1 promoter hypermethylation in both idiopathic patients and unaffected family relatives. Epigenetic models utilizing 49 lymphocyte CpG probes identified cases with an area under the curve of 87.5 percent in blood, while blood-brain correlated differentially methylated regions showed significant enrichment for the kainate-selective glutamate receptor complex driven by GRIK2 and GRIK4. Remarkably, among nurses and shift workers with shift work sleep disorder, a two-week vacation induced reversible DNA methylation remodelling in NMDA receptor-related pathways, specifically at GRIN2C, CREB1, and CAMK2B loci, which directly tracked symptom recovery.

Experimental sleep deprivation studies in animal models and humans demonstrate direct epigenetic consequences of sleep loss, while defining critical frontiers for clinical translation. In rodents, acute sleep deprivation uncouples Bdnf promoter methylation from transcription, while chronic restriction reduces DNMT3A and DNMT3B levels, diminishes Cdk5 promoter methylation, and elevates CDK5 expression and tau phosphorylation. In healthy human trials, acute sleep deprivation alters adipose methylation at CRY1 and PER1 loci, induces 148 lipid-related differentially methylated regions including CD36, shifts SCD1 methylation, and modulates Notch, Wnt, and FAS pathways across peripheral leukocytes exhibiting endogenous daily rhythmicity. However, the review authors highlight that current evidence remains predominantly associative, limited by small sample cohorts, cross-sectional designs, tissue discordance between blood and brain, circadian sampling variability, and confounding medications or chronotypes. Encouraging findings showing that twelve months of compliant continuous positive airway pressure therapy decelerates epigenetic aging emphasize the dynamic utility of epigenetic markers, requiring future validation through large longitudinal multi-omics cohorts and cell-free cerebrospinal fluid profiling.

Subject of Research: DNA methylation patterns across clinical sleep disorders and experimental sleep deprivation

Article Title: DNA methylation in sleep disorders: current evidence and future directions

Article References: A, R., Luo, H., Liu, W., Zheng, J., Guan, Y., Xu, Y., & Chen, S. (2026). DNA methylation in sleep disorders: current evidence and future directions. Frontiers in Neurology, 17, Article 1951276. https://doi.org/10.3389/fneur.2026.1951276

Image Credits: AI Generated

DOI: 10.3389/fneur.2026.1951276

Keywords: DNA methylation, sleep disorders, insomnia, obstructive sleep apnoea, narcolepsy type 1, restless legs syndrome, shift work sleep disorder, sleep deprivation, epigenetic clocks, circadian clock genes, GrimAge acceleration, intermittent hypoxia, neuroplasticity, toll-like receptors, glutamatergic signalling, biological ageing, continuous positive airway pressure, multi-omics